QuantuMDx Group Ltd Has Announced Plans to Expand the Potential of its Q-POC™ Technology and Develop a Quality Control Analytics System for Cell and Gene Therapies (“C>”s), to be Evaluated by GlaxoSmithKline’s C> Platform Group

Newcastle upon Tyne, UNITED KINGDOM, Apr. 17 (Korea Bizwire) – Quality control testing for autologous C&GT’s can be challenging as they are manufactured in small batches and personalised to each patient. However, the C&GT industry is accustomed to manufacturing therapies in large batches, for the treatment of tens of thousands of patients. Within this context, [...]